1Morris DW,Rush AJ,Jain S. Diurnal mood variation in outpatients with major depressive disorder:implications for DSM-Ⅴ from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study data[J].{H}Journal of Clinical Psychiatry,2007,(09):1339-1347.
2Reiter RJ,Tan DX,Maldonado MD. Melatonin as an antioxi dant:physiology versus pharmacology[J].{H}Journal of Pineal Research,2005,(02):215-216.
3Wu YH,Ursinus J,Zhou JN. Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression[J].{H}Journal of affective disorders,2013,(2/3):357-367.
4Srinivasan V,Smits M,Spence W. Melatonin in mood disorders[J].{H}WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY,2006.138-151.
5Turek FW. From circadian rhythms to clock genes in depression[J].{H}International Clinical Psychopharmacology,2007,(Suppl 2):S1-S8.
6Zee PC,Manthena P. The brain's master circadian clock:implications and opportunities for therapy of sleep disorders[J].{H}SLEEP MEDICINE REVIEWS,2007,(01):59-70.
7Weil ZM,Hotchkiss AK,Gatien ML. Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating[J].{H}BRAIN RESEARCH BULLETIN,2006,(06):425-429.
8Cardinali DP,Srinivasan V,Brzezinski A. Melatonin and its analogs in insomnia and depression[J].{H}Journal of Pineal Research,2012,(04):365-375.
9Mendelson WB. Melatonin microinjection into the medialpreoptic area increases sleep in the rat[J].{H}Life Sciences,2002,(17):2067-2070.
10Inyushkin AN,Bhumbra GS,Gonzalez JA. Melatonin modulates spike coding in the rat suprachiasmatic nucleus[J].{H}Journal of Neuroendocrinology,2007,(09):671-681.
4Tardito D, Molteni R, Popoli M, et al. Synergistic mecha- nisms in volved in the antidepressant effects of agomela- tine[J]. Eur Neuropsychopharmacol, 2012,22 (Suppl 3) : $482-486.
5Singh SP,Singh V, Kar N. Efficacy of agomelatine in ma- jor depressive disorder: meta-analysis and appraisal[J]. Int J Neuropsychopharmacol, 2012,15 (3) : 417-428.
6Martinotti G, Sepede G, Gambi F, et al. Agomelatine ver- sus venlafaxine XR in the treatment of anhedonia in major depressive disorder:a pilot study[J]. J Clin Psychophar- macol, 2012,32 (4) .. 487-491.
7Shu L,Sulaiman AH, Huang YS, et al. Comparable effica- cy and safety of 8 weeks treatment with agomelatine 25-- 50 mg or fluoxetine 20--40 mg in Asian out-patients with major depressive disorder[J]. Asian J Psychiatr, 2014 ( 8) :26-32.
8Corruble E,de Bodinat C,Belaidi C, et al. Efficacy of ag- omelatine and escitalopram on depression,subjective sleep and emotional experiences in patients with major depres- sive disorder: a 24-wk randomized, controlled, double- blind trial [J]. Int J Neuropsychopharmacol, 2013, 16 (10) .. 2219-2234.
9TARDITO D,M0 LTENI R,P0 P0 LI M, et al. Synergisticmechanisms in volved in the antidepressant effects of agomelatine [J]. Eur Neuropsychopharmacol, 2012, 22(Suppl 3) :482-486.
10SINGH S P, SINGH V,KAR N.Efficacy of agomelatine inmajor depressive disorder: meta-αnalysis and appraisal [J].Int J Neuropsychophamiacol,2012,15(3) :417-428.
